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Abstract
Background:  The dopamine dysregulation hypothesis of schizophrenia posits that positive,
negative and cognitive symptoms correlate with cortical/subcortical imbalances in dopaminergic
transmission. A functional polymorphism (Val158Met) in the catechol-O-methyltransferase (COMT)
gene is implicated in the pathophysiology of schizophrenia by its effect on prefrontal dopamine
transmission, and its unique impact on prefrontal cognitive and behavioral phenotypes. Cognitive
impairments and negative symptoms in schizophrenia have been hypothesized to be associated with
hypodopaminergic states. Schizophrenia patients with the deficit syndrome are characterized by
primary enduring negative symptoms, impairment on neurocognitive tasks sensitive to frontal and
parietal cortical functioning, and poorer functional outcome compared to non-deficit patients.
Methods:  Eighty-six schizophrenia cases that met DSM-IV criteria for schizophrenia were
recruited. Additional categorization into deficit and nondeficit syndrome was performed using the
Schedule for the Deficit Syndrome (SDS). A healthy comparison group (n = 50) matched to cases
on age and ethnicity was recruited. Allele and genotype frequencies of the Val158Met polymorphism
were compared among healthy controls, and schizophrenia cases with the deficit (n = 21), and
nondeficit syndrome (n = 65).
Results: There was a significant difference in Val/Val genotype frequencies between schizophrenia
cases (combined deficit/nondeficit) and healthy controls (p = 0.004). No significant differences in
allele or genotype frequencies were observed between deficit and nondeficit cases.
Conclusion: Results from this preliminary analysis failed to show an effect of COMT gene on
deficit schizophrenia.
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Background
Schizophrenia is a complex phenotype with a multifacto-
rial etiology. Reducing heterogeneity by identifying alter-
native phenotypes or valid subtypes that reflect specific
neurobiological processes in the pathophysiology of the
disorder is critical to uncovering susceptibility genes [1-3].
The concept of the deficit syndrome subtype of schizo-
phrenia arose in an attempt to reduce clinical heterogene-
ity [4-6]. The deficit syndrome is characterized by primary
(idiopathic) and enduring negative symptoms that persist
through epochs of clinical stability and decompensation.
By definition, idiopathic negative symptoms are not
attributable to paranoid or psychotic withdrawal, depres-
sion, anxiety, or medication side effects. Schizophrenia
patients who do not meet the deficit syndrome criteria are
classified as nondeficit. Compelling evidence supports the
construct validity of the deficit/nondeficit subgrouping on
clinical features and prognosis, risk factors, neurocogni-
tive and biological correlates, and pharmacological
response profiles, and that dysfunction in the neural cir-
cuit that includes the dorsolateral prefrontal cortex
(DLPFC) form the neuropathological basis for the deficit
syndrome [6,7].
The reformulated dopamine hypothesis of schizophrenia
describes interdependent prefrontal hypodopaminergia
(associated with negative and cognitive symptoms) and
subcortical hyperdopaminergia (associated with positive
symptoms) [8]. The COMT gene is implicated in the
pathophysiology of schizophrenia by its effect on prefron-
tal dopamine. A functional single nucleotide polymor-
phism (SNP) (Val158Met) of COMT gene results in two
common variants, Valine (Val) and methionine (Met),
which correspond to low and high synaptic dopamine
respectively [9]. Associations between the Val158Met SNP
and cognitive phenotypes have been described in healthy
and schizophrenia individuals [10-12].
The COMT gene maps to chromosome 22q11.2, a region
implicated in schizophrenia linkage studies, and in velo-
cardiofacial syndrome (VCFS), which is characterized by
psychosis and cognitive deficits [13,14]. COMT is thought
to exert a distinctive effect on prefrontal dopamine-related
information processing because it is primarily expressed
in prefrontal cortical neurons [15,16], and is the principal
enzyme in the degradation of dopamine (up to 60%) in
the DLPFC; a role supported by data from animal studies
[17]. Furthermore, the dopamine transporter, another key
dopamine metabolizing enzyme in the brain is less
expressed in the prefrontal cortex [18]. Deficit schizophre-
nia is characterized by impairments in tasks sensitive to
frontal and parietal cortical functioning [19]. We have
previously demonstrated association between COMT 158
Val allele and schizophrenia in a biracial cohort of
patients from the Baltimore Metropolitan area [20]. In the
current report, we have extended our previous study to
evaluate the association between the variant Val allele and
deficit/nondeficit schizophrenia. We hypothesized that
the Val allele would occur more frequently in deficit than
in nondeficit schizophrenia.
Materials and methods
Eighty-six unrelated schizophrenia individuals were
recruited from the Maryland Psychiatric Research Center
(MPRC). Healthy controls (n = 50) were recruited through
newspaper advertisements targeting the same geographic
region. All participants gave written informed consent,
which was approved by the University of Maryland Insti-
tutional Review Board. Additional evaluation of the
capacity to sign consent was performed on patients to
assess their understanding of the study [21]. As in our pre-
vious study, there was no COMT genotype or allele asso-
ciation in African-American subjects, so this group was
not included in the current study (n = 80). Patients met
the Structured Clinical Interview for DSM-IV (SCID-IV)
[22] criteria for schizophrenia or schizoaffective disorder.
Additional categorization into deficit (n = 21), and non-
deficit syndrome (n = 65) was performed with the Sched-
ule for the Deficit Syndrome (SDS). For the diagnosis of
deficit schizophrenia, this instrument requires the pres-
ence of two or more idiopathic and enduring negative
symptoms (Kirkpatrick et al, 1989). Inter-rater reliabilities
among the clinical interviewers were above 0.80 (inter-
class correlation). The Structured Interview for DSM-IV
Personality Diagnoses (SIDP) [23], and Family History-
Research Diagnostic Criteria (FH-RDC) [24] were admin-
istered in controls. Healthy controls had no Axis I diag-
noses, or schizophrenia spectrum personality disorders.
Genotyping methods are described elsewhere [20].
Briefly, venous whole blood was collected and DNA iso-
lated by standard means. COMT Val158Met SNP was deter-
mined as a restriction fragment length polymorphism
(RFLP) after PCR amplification according to the method
of Egan et al. (2001).
Fisher's exact test was used to evaluate whether the
observed distribution of COMT Val158Met genotypes was
consistent with that expected under Hardy Weinberg equi-
librium. Nominal logistic regression (with age and sex as
predictor variables) was used to determine the effect of
genotype on disease status under an additive genetic
model (i.e., by assigning values of -1, 0, and 1 to the three
genotype classes). We first evaluated the effect of genotype
on the total schizophrenia endpoint, combining the defi-
cit and nondeficit subtypes. We then evaluated genotype
effects on the deficit only schizophrenia endpoint.Behavioral and Brain Functions 2006, 2:42 http://www.behavioralandbrainfunctions.com/content/2/1/42
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Results
The sample consists of 136 European-American subjects
(21 deficit cases, 65 nondeficit cases, and 50 healthy con-
trols) presented in Table 1. The observed COMT genotype
distributions were consistent with that expected under
Hardy Weinberg equilibrium. Comparisons of COMT
genotype frequencies between cases and controls are pre-
sented in Table 1. COMT genotype was significantly asso-
ciated with schizophrenia (deficit and nondeficit
combined; age- and sex-adjusted Odds Ratio = 3.24, p =
0.004 by genotype test), with Val allele frequencies of 0.68
and 0.43, in cases and controls, respectively. In contrast,
genotype (and allele) frequencies did not differ between
deficit and nondeficit cases (allele frequencies 0.74 and
0.66, respectively; age- and sex-adjusted p = 0.8). Deficit
schizophrenia was observed in one female: COMT genetic
variation has been previously shown to produce sexual
dimorphism in brain dopamine levels; we repeated the
analyses comparing COMT genotype between deficit and
nondeficit subtypes in males only. We again observed that
genotype (and allele) frequencies did not differ between
both groups (allele frequencies 0.72 and 0.58, respec-
tively; p = 0.19). Given the small sample size, we esti-
mated the least detectable difference in allele frequencies
that could have been observed in our sample between def-
icit and nondeficit cases. Given the observed Val allele fre-
quency of 0.66 in nondeficit cases, the frequency in the
deficit group would have had to have been less than 0.42
or greater than 0.87 in order to detect a significant differ-
ence between groups (at alpha = 0.05) with 80% power.
Discussion
In this report we did not observe a significant difference
between deficit and nondeficit schizophrenia subtypes in
either COMT allele or genotype frequencies. Our report
however provides an extension of our earlier finding of
association between COMT158Val allele and schizophre-
nia in a larger sample of European-American subjects with
the addition of deficit schizophrenia individuals. Similar
to our prior report, we failed to find association between
COMT gene and schizophrenia in the African-American
subgroup. This suggests that COMT allele frequencies
might be different in both ethnic groups in this Baltimore
sample. To avoid potential population substratification,
we did not include African-Americans in the current
report. In our previous study based on 61 European-
Americans with schizophrenia, we observed allele fre-
quencies of 0.62 and 0.50 in cases and healthy controls (p
= 0.04). The differences in allele frequencies persisted,
and indeed increased in this study on a modestly
expanded sample (to 0.680 vs. 0.430), which includes 86
European-American schizophrenia cases presented in this
report. Evidence from family-based and case-control stud-
ies generally suggest that COMT Val158Met polymorphism
might be associated with schizophrenia [25] with some
negative reports [26,27].
Table 1: Demographic information and COMT genotype
Schizophrenia Subjects Healthy controls Total
Sex Nondeficit Deficit Total patients
F e m a l e N2 812 9 2 2 5 1
Age Mean (SD) 47.08 (8.94) 55 (0.0) 47.36 (8.91) 44.31 (17.59) 46.04 (13.29)
Val-Val 16 1 17 6 23
V a l - M e t 1 101 1 1 0 2 1
M e t - M e t 10167
Male N 37 20 57 28 85
Age Mean (SD) 43.80 (10.14) 43.74 (11.12) 43.78 (10.40) 46.89 (17.87) 44.80 (13.30)
Val-Val 14 10 24 3 27
V a l - M e t 1 592 4 1 5 3 9
Met-Met 8 1 9 10 19
Total N 65 21 86 50 136
Age Mean (SD) 45.21 (9.71) 44.28 (11.12) 44.98 (10.01) 45.76 (17.62) 45.27 (13.26)
Val-Val 30 11 41 9 50
V a l - M e t 2 693 5 2 5 6 0
Met-Met 9 1 10 16 26
N = number
SD = standard deviation
Val = Valine variant allele
Met = Methionine variant allele
COMT = catechol-O-methyltransferaseBehavioral and Brain Functions 2006, 2:42 http://www.behavioralandbrainfunctions.com/content/2/1/42
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The main limitation of this study is the small sample size,
which may have limited detecting associations of only
modest size between COMT gene and deficit/nondeficit
subtypes. The differences are so small that the power
needed to detect a significant difference between both
subtypes would indeed require a large sample. However,
our findings are unlikely due to type II error. Our reported
allele and genotype frequencies were similar between the
deficit and nondeficit schizophrenia subgroups, but con-
siderably higher than the frequencies observed in healthy
controls. In this sample, the patient group is comprised of
a significantly higher proportion of males than the control
group. Furthermore, there are substantially more males in
the deficit group, which is consistent with prior reports on
deficit schizophrenia (Kirkpatrick et al, 2001). Prior stud-
ies have reported a sexual dimorphism in COMT-associ-
ated dopamine levels on several neuropsychiatric
phenotypes in a region-specific manner, particularly in
the frontal cortex [28,29]. Analyses using a regression
model controlled for age and sex effects on our COMT
findings in this Baltimore sample.
Conclusion
The results do not support a differential COMT gene effect
on the deficit/nondeficit subtypes of schizophrenia.
Future studies in larger independent samples investigating
joint interactions with other candidate dopamine system
genes (e.g. dopamine transporter gene [DAT1]) and
COMT gene on schizophrenia endophenotypes are war-
ranted.
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